Abstract:Background: Diabetic kidney disease (DKD) is one of the most serious microvascular complications of diabetes mellitus (DM) and the leading cause of chronic kidney disease (CKD) worldwide. Since obesity and type 2 DM (T2DM) are considered as inflammatory conditions, thus reducing their accompanied systemic inflammation may lessen their complications. Sestrin 2 belongs to a group of stress induced proteins which are produced in response to oxidative stress, inflammation and DNA damage. Betatrophin; a hormone that stimulates the growth, proliferation and mass expansion of pancreatic beta-cells and improves glucose tolerance. The objective of the study was to evaluate levels of serum Sestrin 2 and betatrophin in patients with different stages of diabetic nephropathy (DN)) and compare results with healthy control. Methods: This cross sectional study was carried out on 60 patients above 18 years old, recruited from Tanta University hospitals out patients clinics and 20 apparently healthy individuals of matched sex and age as a control group. Participants were divided into two groups: group I: 20 normal subjects as control group and group II: 60 patients with type 2 DM,. further subdivided in to three equal groups: group 1IIA(20 patients) with normo-albuminuria (ACR < 30 mg/g), group IIB (20 patients) with micro albuminuria (ACR = 30 to 300 mg/g) and group IIC (20 patients) with macro albuminuria (ACR > 300 mg/g). They were subjected to detailed history taking, careful clinical examination and laboratory investigations including blood urea, serum creatinine, estimated glomerular filtration rate (eGFR), urinary albumin creatinine ratio, and specific laboratory tests for Sestrin 2 and Betatrophin by using ELISA technique. Results: Serum Sestrin 2 significantly decreased, while serum betatrophin level significantly increased in macroalbuminuric group compared to control and other 2 diabetic groups (P value < 0.05). The cut off value of serum sestrin 2 was 0.98 ng/ml with sensitivity 99%, specificity 66% while the cut off value of serum betatrophin was > 98.25 ng/ml with sensitivity 98%, specificity 82%. Serum betatrophin positively correlated with age, fasting, 2 h postprandial, BMI, triglyceride, total cholesterol, serum creatinine, blood urea, UACR, and negatively correlated with eGFR and serum albumin. Serum Sestrin 2 positively correlated with serum albumin. BMI, serum urea, UACR and serum albumin. Serum betatrophin are found to be risk factors or predictors for diabetic nephropathy. Conclusions: Patients with DN, particularly the macroalbuminuria group, had a significant increase in betatrophin levels and a significant decrease in serum Sestrin 2 level. The function of Sestrin 2 is compromised in DN, and restoring it can reverse a series of molecular alterations with subsequent improvement of the renal functions, albuminuria and structural damage.

Increased Circulating Levels Of Betatrophin In Newly Diagnosed Type 2 Diabetic Patients

Circulating Betatrophin Levels Are Increased in Patients with Type 2 Diabetes and Associated with Insulin Resistance

Betatrophin Acts As a Diagnostic Biomarker in Type 2 Diabetes Mellitus and is Negatively Associated with HDL-Cholesterol

Circulating Betatrophin in Patients with Type 2 Diabetes: A Meta-Analysis.

Circulating Betatrophin Correlates With Triglycerides And Postprandial Glucose Among Different Glucose Tolerance Statuses-A Case-Control Study

Serum betatrophin level increased in subjects with metabolic syndrome: a case-control study

Positive Association Between Betatrophin and Diabetic Retinopathy Risk in Type 2 Diabetes Patients

Effect of short-term continuous subcutaneous insulin infusion treatment on serum betatrophin in newly diagnosed type 2 diabetes

Increased Circulating Full-Length Betatrophin Levels in Drug-Naïve Metabolic Syndrome

Circulating Levels of Betatrophin and Irisin Are Not Associated with Pancreatic Β-Cell Function in Previously Diagnosed Type 2 Diabetes Mellitus Patients

Betatrophin Provides a New Insight into Diabetes Treatment and Lipid Metabolism (Review).

Serum Betatrophin Concentrations Are Significantly Increased in Overweight but Not in Obese or Type 2 Diabetic Individuals.

Betatrophin and Insulin Resistance

Serum betatrophin level increased in subjects with nonalcoholic fatty liver disease

Relationship Between Diabetes and Betatrophin

The Correlation Between Circulating Betatrophin and Insulin Resistance in General Population: A Meta-Analysis

Association of Betatrophin with Metabolic Characteristics in Overweight/obese and Lean Women with PCOS

[Elevated serum levels of betatrophin in patients with polycystic ovary syndrome and the influential factors]

Evaluation of serum levels of sestrin 2 and betatrophin in type 2 diabetic patients with diabetic nephropathy

Association of Serum 25-Hydroxyvitamin D3 with Islet Β Cell Function and Insulin Resistance in New Onset Type 2 Diabetics

Emerging regulation and function of betatrophin